Earnings ·
Shattuck Labs reported a net loss of $15.2 million ($0.12 per share) for the quarter ended June 30, 2026, compared to…
STTKShattuck Labs, Inc.
Shattuck Labs reported a net loss of $15.2 million ($0.12 per share) for the quarter ended June 30, 2026, compared to a $12.5 million loss in the prior year period. R&D expenses increased to $11.7 million from $8.7 million as the company advances its pipeline. The firm holds approximately $208.3 million in cash and investments, sufficient to fund operations into 2029. Phase 1 data for lead candidate SL-325 showed a favorable safety profile and durable TL1A blockade, supporting an upcoming Phase 2b trial in Crohn's disease expected in Q3 2026. Additionally, the company announced progress on bispecific candidate SL-846 and completed capital raises totaling approximately $143.3 million through public offerings and warrant exercises. Shattuck Labs is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for inflammatory and immune-mediated diseases.